lcar-aio cells
Cell therapyexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 14, 2022 (NCT05318963)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD20Immunity, passive
MS4A1 immunity, passive
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
- CD22Immunity, passive
CD22 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06869278 | Phase 1 | Mar 15, 2025 | GenScript, Huazhong University of Science and Technology |
| NCT06866080 | Early Phase 1 (Phase 1) | Feb 10, 2025 | GenScript |
| NCT06653556 | Early Phase 1 (Phase 1) | Oct 20, 2024 | GenScript, Government of China, Huazhong University of Science and Technology |
| NCT05292898 | Phase 1 | Mar 14, 2022 | Chinese Academy of Medical Sciences, GenScript |
| NCT05318963 | Phase 1 | Mar 14, 2022 | Chinese Academy of Medical Sciences, GenScript |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GenScript | For profit | 5 | 1 | 1 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 2 | 1 | 2022 |
| Huazhong University of Science and Technology | Academic/Hospital | 2 | 2 | 1 | 2024 |
| Government of China | Government | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1